Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Medlab Clinical Ltd (MDC.AX)

Medlab Clinical Ltd (MDC.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Medlab Clinical Ltd 50 Kings Park Road Level 2 West Perth WA 6005 AUS

https://www.medlab.co P: +61 281880311

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Medlab Clinical Ltd is an Australian biotechnology company that specializes in the application of NanoCelle drug delivery technology to existing and new pharmaceuticals to empower patients with chronic diseases and mental health conditions and enhance their lives.. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B, and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.

Key Statistics

Overview:

Market Capitalization, $K 15,071
Shares Outstanding, K 2,284
% of Institutional Shareholders 0.04%

Financials:

Annual Sales, $ 12 K
Annual Net Income, $ -2,131 K

Growth:

1-Year Return -64.80%
3-Year Return -82.40%
5-Year Return -94.36%
5-Year Revenue Growth -70.62%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.93
Dividend Payout Ratio 0.00%
Most Recent Split 1-150 on 08/02/22

MDC.AX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -993.60%
Return-on-Assets % -130.89%
Profit Margin % -17,913.57%
Debt/Equity N/A
Price/Sales 0.08
Price/Book 1.87
Book Value/Share 3.54
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.